John Sarbanes

Even that industry is beginning to shift its position, leaving the Trump administration and the President's position really increasingly as an outlier.

When I am trying to figure out why political leaders are moving in the opposite direction from where the public is moving or where science in this case is moving or the experts are moving, I have found it pretty useful up here to follow…

The fossil fuel industry has funded efforts for years to confuse and mislead the public on climate science.

I want to get back to this idea that adding a citizenship question to the census was important for enforcing the Voting Rights Act, because I think that was a rationale that was concocted by your department and then foisted upon the DOJ…

I think that you and the Department are in a somewhat precarious position increasingly so, partly because of the substance of the decision with respect to the citizenship question, but even more so because of the process by which it was…

But I think what Congressman Rush has proposed makes perfect sense in the wake of the Actavis case.

I was very happy to work on a Biosimilars Competition Act that we were able to get passed into law last year.

I think what Congressman Rush has proposed makes perfect sense in the wake of the Actavis case.

The value of creating a kind of bright line standard here makes a lot of sense to me.

I strongly support, as you probably are surprised to hear, Congressman Rush's proposal.

Should they be signed into law, it is troubling that agency witnesses were not considered.

It is unthinkable, that the Food and Drug Administration was not invited to testify at this hearing.

Bipartisanship is asking for my input, not just my vote.

The public has a strong appetite. It fluctuates over the course of different administrations and congresses.

Do you understand my concern about how monthly limits could be manipulated based on experience or anticipation of what will be coming in?

The reason that concerns me is there is potential for politics to get in the mix.

The Department of the Interior proposed a rule in December, I believe, that would restrict public access to its records.

I am particularly troubled at this notion that the monthly limit could just change based on the--

The FOIA Improvement Act is a prime example of how Members of Congress from both parties can work together to achieve positive results for the American people.

Public Citizen Statement; submitted by Mr. Sarbanes

I think HHS and FDA have to put a plan in place for retroactively reviewing the safety and efficacy of existing opioid projects.

I am worried that whatever the standards are that are being applied are not achieving the goals that the public would want to see in terms of kind of rigorous decisions about what is safe and what is not safe.

So how is HHS going to hold pharmaceutical manufacturers accountable for drug-marketing strategies that are boosting profits while harming our communities?

I think it is indefensible and there is going to be a lot of continued inquiry in that regard.

I just wanted to make sure the record was clear on a couple of things.